相关实验视频
Updated: Jun 13, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
阿瓦科潘作为ANCA相关血管炎的附加疗法:药理学概述
Vladimir Tesar1, Jan Miroslav Hartinger2, Zdenka Hruskova1
1Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
阿瓦科潘是一种C5a受体抑制剂,为ANCA相关血管炎 (AAV) 提供一种葡萄糖皮质醇节约的选择. 临床试验表明,它与高剂量葡萄糖皮质类药物相比并非劣,更优越,改善了结局和生活质量.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与ANCA相关的血管炎 (AAV) 是一种严重的自身免疫性疾病,导致器官损伤.
- 目前的治疗方法 (cyclophosphamide,rituximab,glucocorticoids) 改善了结果,但导致了严重的并发症和复发.
- 替代补充通路和C5a受体信号传递与AAV病变发生有关.
研究的目的:
- 评估阿瓦科潘的药理动力学/药理动力学特性,临床疗效和安全性.
- 审查可用的临床试验和阿瓦科班在AAV治疗中的现实世界经验.
主要方法:
- 第三阶段临床试验比较阿瓦科班与高剂量葡萄糖皮质体与环胺或利图西马布.
- 评估临床疗效,安全性,功能和生活质量.
主要成果:
- 与标准治疗相比,阿瓦科潘在6个月后表现为非劣势,在12个月后表现为优势.
- 阿瓦科潘治疗耐受性很好,在严重的脏AAV中改善了生活质量和功能.
- 阿瓦科班是一种CYP 3A4抑制剂和基质,需要考虑药物相互作用.
结论:
- 阿瓦科潘是一种可行的糖皮质激素储存剂,可用于活性AAV,可能降低毒性并改善长期结局.
- 阿瓦科潘为高剂量葡萄糖皮质类药物提供了替代品,提高了患者的生活质量.
- 由于阿瓦科班的CYP 3A4活性,需要仔细管理药物相互作用.
更多相关视频
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...